Research conducted at AstraZeneca has updated our knowledge about bipolar disorder therapy
2007 NOV 19 -- Research findings, 'Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder,' are discussed in a new report. In this recently published study, investigators in the United States conducted a study "To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium The pharmacokinetics and short-term tolerability and safety of coadministered quetiapine and divalproex were examined in adults with schizophrenia/schizoaffective disorder (Cohort A) or bipolar disorder (Cohort B) in an open-label, parallel, 2-cohort drug-interaction study conducted at three centers in the United States. Cohort A was administered quetiapine (150 mg bid) prospectively for 13 days, with divalproex (500 mg bid) added on days 6-13." "Cohort B was administered divalproex (500 mg bid) for 16 days, with quetiapine (150 mg bid) added on days 9-16. Quetiapine and valproic acid plasma concentration-time data over a 12-h steady-state dosing interval were used to determine C(max), T(max), C(min), area under the plasma concentration-time curve (AUC(tau)), and oral clearance (CL/F) In Cohort A (n=18), addition of divalproex did increase the C(max) of quetiapine by 17% but did not change AUC(tau). In Cohort B (n=15), addition of quetiapine decreased both total valproic acid C(max) and AUC(tau) by 11%," wrote H.R. Winter and colleagues, AstraZeneca. The researchers concluded: "No differences were observed in adverse events (AEs) with either quetiapine or divalproex monotherapy or their combination Combination therapy with quetiapine (150 mg bid) and divalproex (500 mg bid) resulted in small and statistically non-significant pharmacokinetic changes." Winter and colleagues published their study in Human Psychopharmacology (Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Human Psychopharmacology, 2007;22(7):469-76). For additional information, contact H.R. Winter, AstraZeneca Pharmaceuticals LP, Wilmington, DE USA.. The publisher of the journal Human Psychopharmacology can be contacted at: John Wiley & Sons Ltd., the Atrium, Southern Gate, Chichester PO19 8SQ, W Sussex, England. Keywords: United States, Wilmington, Bipolar Disorder Therapy, Anticonvulsant, Antimanic, Antipsychotic, Bipolar Disorder, Divalproex Sodium, Drug Development, Drugs, GABA Agent, Manic-Depressive Illness, Pharmaceuticals, Pharmacokinetics, Psychiatry, Psychopharmacology, Quetiapine Fumarate, Schizophrenia, Therapies, Therapy, Treatment, Valproic Acid. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
